Tag Archives: statins

Colon Cancer Prevention Trial Seeking New Patients

Can drugs used to help lower cholesterol also keep colon cancer from returning?  Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) are seeking patients for a one-year clinical trial to determine if cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps and/or recurrent colorectal cancer. The NSABP trial is sponsored by the National Cancer Institute and has recently expanded to include patients with stage 0, I, II or III colon cancer at diagnosis. Patients can enter the study up to one year after their initial diagnosis. In 2011, Fight Colorectal Cancer’s late Director of Research Communications Kate Murphy wrote about the trial and its efforts

National polyp prevention trial needs participants

  Do cholesterol-lowering drugs help prevent CRC? You might be able to help answer that question. A national research project needs people who have been treated for early-stage (stage I or II) colorectal cancer in the past year. There have been tantalizing hints that cholesterol-lowering drugs (statins) might help prevent the growth of precancerous (adenomatous) polyps and/or recurrent colorectal cancer. Millions of Americans already take these statins to protect against heart attacks. We also know that people who have had early-stage colorectal cancer have up to a 50% chance of developing new polyps within 3 years. Some studies have shown that people who had taken statins had lower rates of

New Opportunity for Patients Finishing Colon Cancer Treatment

Are you finished with surgery or chemotherapy for early stage colon cancer? Would you like a chance to see if a new experimental treatment can reduce your risk of A new polyp in your colon? Colon cancer spreading beyond your colon? A new colon cancer? Researchers at the National Surgical Adjuvant Breast and Bowel Project (NSABP) would like to talk to you about a clinical trial exploring whether a statin drug can reduce the risk of new polyps, colon cancer recurrence, or a new primary colon cancer. In the P-5 clinical trial stage I and II colon cancer patients will be randomly assigned to take either rosuvastatin (Crestor®) or an

Top